Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs

Ann T Farrell1, Kirsten B Goldberg1, Richard Pazdur1,2

  • 1Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, and.

Blood
|August 5, 2017
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos